Currently, cognitive impairment of patients diagnosed with Alzheimer's disease (AD) is measured using the 'Mini-Mental State Examination' (MMSE) test, which involves monitoring answers to five types of questions and using an algorithm to score patients. However, the MMSE test has received criticism, with factors such as educational background being shown to affect scores.
A new research article from Pablo Moscato and colleagues, from the Hunter Medical Research Institute and University of Newcastle (Australia), presents a multivariate approach intended to improve on the MMSE test.
The study saw an analysis of 3717 patients from the Coalition Against Major Diseases dataset, with five groups of patients identified: cognisant, inattentive, forgetful, distant and absent. The groups were distinct in terms of both characteristics and prognostics. Furthermore, out of the five MMSE questionnaire categories only three were found to be critical for grouping: registration, attention and recall.
"This project [was] motivated by the observation that the CAMD database is an aggregation of several trials that employed varying cognitive test versions and are therefore generally incompatible or not directly comparable among each other in terms of the calculated patients' overall cognitive performance," noted the authors. "Our goal [was] to resolve which test categories contribute to the patient group differentiation the most and to build a model that can be employed to reliably assign a patient to an AD cognitive group associated with certain impairment characteristics and clinical prognosis, independent of the questionnaire version."
The researchers also analyzed transitions between groups. Inna Tishchenko, first author, commented: "we analyzed the cognitive performance of AD patients over a time frame of up to 4 years and obtained hints that multivitamins might slow progression only in the group that presents a mild impairment in recalling." Furthermore, they provide insight into the progression pathways of AD, and highlight the possible existence of subgroups.
The model presented by the group is freely available for use via the supplementary material.
The article is available free to read at: http://www.
About Future Science OA
Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
About Future Science Group Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.